Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $45.8462.

Several equities research analysts have weighed in on the company. Guggenheim lowered their target price on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a report on Friday, May 8th. Piper Sandler lowered their target price on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays cut Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their target price for the stock from $29.00 to $14.00 in a report on Monday, April 20th. Clear Str cut Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Truist Financial upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Monday, May 4th.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $14.03 on Tuesday. The company has a market cap of $855.61 million, a P/E ratio of -7.63 and a beta of 2.58. The business’s 50 day moving average price is $14.42 and its 200-day moving average price is $16.83. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. As a group, equities analysts predict that Janux Therapeutics will post -1.71 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at $457,265.90. This represents a 5.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 7.90% of the stock is owned by company insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Irenic Capital Management LP acquired a new stake in Janux Therapeutics during the first quarter worth about $10,645,000. ADAR1 Capital Management LLC boosted its position in Janux Therapeutics by 21.6% during the first quarter. ADAR1 Capital Management LLC now owns 298,546 shares of the company’s stock worth $4,150,000 after purchasing an additional 53,094 shares in the last quarter. Rock Springs Capital Management LP boosted its position in Janux Therapeutics by 2.3% during the first quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock worth $5,101,000 after purchasing an additional 8,211 shares in the last quarter. Quantinno Capital Management LP boosted its position in Janux Therapeutics by 7.6% during the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after purchasing an additional 1,846 shares in the last quarter. Finally, Rangeley Capital LLC boosted its position in Janux Therapeutics by 382.0% during the first quarter. Rangeley Capital LLC now owns 122,500 shares of the company’s stock worth $1,703,000 after purchasing an additional 97,086 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.